Recent discussions on X about Twist Bioscience (TWST) have centered around the company’s latest collaboration with Element Biosciences, particularly the launch of the Trinity Freestyle Fast Hybridization workflow for the AVITI sequencing platforms. Many users have expressed intrigue over this development, highlighting the potential for this high-speed sequencing solution to position Twist as a key player in synthetic biology and AI-driven drug discovery. The conversation often draws comparisons to major industry innovators, with some seeing the company as a critical infrastructure provider in DNA synthesis.
Additionally, there’s a notable focus on the stock’s performance, with comments pointing to its outperformance in the biotech sector year-to-date, despite being significantly below its 52-week high. Some participants in the discussion are optimistic about the company’s long-term growth, driven by the increasing democratization of synthetic DNA production, while others remain cautious due to past volatility. This mix of enthusiasm and skepticism keeps the dialogue dynamic and engaging.
Note: This discussion summary was generated from an AI condensation of post data.
Twist Bioscience Insider Trading Activity
Twist Bioscience insiders have traded $TWST stock on the open market 54 times in the past 6 months. Of those trades, 0 have been purchases and 54 have been sales.
Here’s a breakdown of recent trading of $TWST stock by insiders over the last 6 months:
- PATRICK JOHN FINN (President and COO) has made 0 purchases and 9 sales selling 56,281 shares for an estimated $1,829,909.
- EMILY M. LEPROUST (Chief Executive Officer) has made 0 purchases and 10 sales selling 53,460 shares for an estimated $1,693,077.
- PAULA GREEN (SVP of Human Resources) has made 0 purchases and 10 sales selling 15,313 shares for an estimated $483,961.
- DENNIS CHO (See Remarks) has made 0 purchases and 14 sales selling 12,828 shares for an estimated $409,278.
- ADAM LAPONIS (Chief Financial Officer) has made 0 purchases and 3 sales selling 9,242 shares for an estimated $306,353.
- ROBERT F. WERNER (Chief Accounting Officer) has made 0 purchases and 8 sales selling 4,779 shares for an estimated $143,329.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Twist Bioscience Hedge Fund Activity
We have seen 112 institutional investors add shares of Twist Bioscience stock to their portfolio, and 140 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EDGEPOINT INVESTMENT GROUP INC. added 1,272,732 shares (+114.3%) to their portfolio in Q2 2025, for an estimated $46,823,810
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,222,874 shares (-50.1%) from their portfolio in Q2 2025, for an estimated $44,989,534
- INVESCO LTD. removed 1,036,300 shares (-30.6%) from their portfolio in Q2 2025, for an estimated $38,125,477
- THRIVENT FINANCIAL FOR LUTHERANS removed 902,516 shares (-99.3%) from their portfolio in Q2 2025, for an estimated $33,203,563
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 790,341 shares (-13.5%) from their portfolio in Q2 2025, for an estimated $29,076,645
- POINT72 ASSET MANAGEMENT, L.P. added 725,537 shares (+50.6%) to their portfolio in Q2 2025, for an estimated $26,692,506
- BLACKROCK, INC. added 643,580 shares (+11.4%) to their portfolio in Q2 2025, for an estimated $23,677,308
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Twist Bioscience Analyst Ratings
Wall Street analysts have issued reports on $TWST in the last several months. We have seen 5 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Barclays issued a "Overweight" rating on 10/02/2025
- Goldman Sachs issued a "Buy" rating on 05/06/2025
- Guggenheim issued a "Buy" rating on 05/06/2025
- Baird issued a "Outperform" rating on 05/06/2025
- JP Morgan issued a "Underweight" rating on 05/06/2025
To track analyst ratings and price targets for Twist Bioscience, check out Quiver Quantitative's $TWST forecast page.
Twist Bioscience Price Targets
Multiple analysts have issued price targets for $TWST recently. We have seen 6 analysts offer price targets for $TWST in the last 6 months, with a median target of $43.0.
Here are some recent targets:
- Vijay Kumar from Evercore ISI Group set a target price of $42.0 on 10/07/2025
- Luke Sergott from Barclays set a target price of $40.0 on 10/02/2025
- Matthew Sykes from Goldman Sachs set a target price of $48.0 on 05/06/2025
- Subbu Nambi from Guggenheim set a target price of $50.0 on 05/06/2025
- Catherine Ramsey from Baird set a target price of $44.0 on 05/06/2025
- Rachel Vatnsdal from JP Morgan set a target price of $33.0 on 05/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
